| Phase IV Study Demonstrates Local Tumor Control in 94% of Primary and 57% of Recurrent Tumors and Enhanced Quality of Life in Patients Treated with OMS ElectroChemotherapy SAN DIEGO, April 23, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carc...continued ONCS |
Monday, April 23, 2012
OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment